ANTENGENE

# Antengene Corporation Limited
# 德琪醫藥有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6996)**

## VOLUNTARY ANNOUNCEMENT
## RECEIPT OF USD60 MILLION UPFRONT PAYMENT FROM UCB FOR ATG-201

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest developments of the Company.

Reference is made to the announcement of the Company dated March 4, 2026, in relation to the entering into of a worldwide exclusive license agreement (the "**Agreement**") for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, between the Company as licensor and UCB as the licensee.

The board of directors of the Company (the "**Board**") is pleased to announce that the Group has received the initial USD60 million upfront payment from UCB. The receipt of the upfront payment from this landmark Agreement with UCB has further strengthened the Group's cash position, providing robust financial support for the advancement of our innovative drug pipeline and accelerating benefits to more patients.

**ATG-201 may not ultimately be successfully developed and commercialized. The Company's shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By the order of the Board
**Antengene Corporation Limited**
**Dr. Jay Mei**
*Chairman*

Hong Kong, July 13, 2026

*As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.*